Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics

17 Mar, 2021

Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
Photo by Charles Forerunner on Unsplash

– Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102m Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio.
D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures.
– Sepsis caused more than five million deaths annually worldwide before the COVID-19 pandemic, and severe COVID-19 has been recognized as viral sepsis. In addition, antibiotic resistance is directly responsible for more than 700,000 deaths annually worldwide.

Big Data Bioinformatics Biotechnology Health Care Health Diagnostics North America
Crunchbase icon

Content report

The following text will be sent to our editors: